Am J Cardiol. 1995 May 1;75(14):894-903. doi: 10.1016/s0002-9149(99)80683-3.
The Diabetes Control and Complications Trial (DCCT), a multicenter, randomized, controlled clinical trial, demonstrated that intensive diabetes therapy delays the onset and slows the progression of retinopathy, nephropathy, and neuropathy in patients with insulin-dependent diabetes mellitus. This study presents the effect of intensive therapy on atherosclerosis-related events and associated risk factors. Patients (n = 1,441) between the ages of 13 and 39 years with insulin-dependent diabetes mellitus were randomly assigned to conventional or intensive diabetes treatment. The patients were free of cardiovascular disease at baseline. Patients with hypertension, hypercholesterolemia, or obesity were excluded. Average length of follow-up was 6.5 years (range 3.5 to 9). The study used standardized definitions of macrovascular events, verification of such events, and central laboratories for determination of lipids and the grading of electrocardiograms. The number of combined major macrovascular events was almost twice as high in the conventionally treated group (40 events) as in the intensive-treatment group (23 events), although the differences were not statistically significant (p = 0.08). There were no differences in the cumulative incidence of hypertension. Mean total serum cholesterol, calculated low-density lipoprotein cholesterol, and triglycerides were significantly reduced in the intensive-treatment group (p < or = 0.01), as was the development of low-density lipoprotein cholesterol levels > 160 mg/dl. Weight gain was significantly increased in the intensive-treatment group (p < 0.001). There were no differences in cigarette smoking habits, consumption of alcohol, or aspirin use between treatment groups. The reduction in some, but not all, cardiovascular risk factors suggests a potential beneficial effect of intensive therapy on macrovascular disease in insulin-dependent diabetes mellitus.
糖尿病控制与并发症试验(DCCT)是一项多中心、随机、对照临床试验,该试验表明强化糖尿病治疗可延缓胰岛素依赖型糖尿病患者视网膜病变、肾病和神经病变的发生并减缓其进展。本研究呈现了强化治疗对动脉粥样硬化相关事件及相关危险因素的影响。13至39岁的胰岛素依赖型糖尿病患者(n = 1441)被随机分配至常规糖尿病治疗组或强化糖尿病治疗组。患者在基线时无心血管疾病。排除患有高血压、高胆固醇血症或肥胖症的患者。平均随访时长为6.5年(范围3.5至9年)。该研究采用了大血管事件的标准化定义、此类事件的核查以及用于测定血脂和心电图分级的中心实验室。在常规治疗组(40例事件)中合并的主要大血管事件数量几乎是强化治疗组(23例事件)的两倍,尽管差异无统计学意义(p = 0.08)。高血压的累积发病率无差异。强化治疗组的平均总血清胆固醇、计算得出的低密度脂蛋白胆固醇和甘油三酯显著降低(p≤0.01),低密度脂蛋白胆固醇水平>160 mg/dl的发生率也是如此。强化治疗组的体重增加显著(p<0.001)。治疗组之间在吸烟习惯、酒精摄入量或阿司匹林使用方面无差异。部分而非全部心血管危险因素的降低表明强化治疗对胰岛素依赖型糖尿病患者的大血管疾病可能具有有益作用。